189 related articles for article (PubMed ID: 33939292)
1. Trametinib therapy for children with neurofibromatosis type 1 and life-threatening plexiform neurofibroma or treatment-refractory low-grade glioma.
Ronsley R; Hounjet CD; Cheng S; Rassekh SR; Duncan WJ; Dunham C; Gardiner J; Ghag A; Ludemann JP; Wensley D; Rehmus W; Sargent MA; Hukin J
Cancer Med; 2021 Jun; 10(11):3556-3564. PubMed ID: 33939292
[TBL] [Abstract][Full Text] [Related]
2. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
3. Recalcitrant trametinib-induced paronychia treated successfully with topical timolol in a pediatric patient.
Martínez-de-Espronceda I; Bernabeu-Wittel J; Azcona M; Monserrat MT
Dermatol Ther; 2020 Jan; 33(1):e13164. PubMed ID: 31705590
[TBL] [Abstract][Full Text] [Related]
4. Trametinib for the treatment of recurrent/progressive pediatric low-grade glioma.
Manoharan N; Choi J; Chordas C; Zimmerman MA; Scully J; Clymer J; Filbin M; Ullrich NJ; Bandopadhayay P; Chi SN; Yeo KK
J Neurooncol; 2020 Sep; 149(2):253-262. PubMed ID: 32780261
[TBL] [Abstract][Full Text] [Related]
5. Impact of trametinib on the neuropsychological profile of NF1 patients.
Lalancette E; Cantin É; Routhier MÈ; Mailloux C; Bertrand MC; Kiaei DS; Larouche V; Tabori U; Hawkins C; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; McKeown T; Ospina LH; Vairy S; Ramaswamy V; Coltin H; Sultan S; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Caru M; Dehaes M; Jabado N; Perreault S; Lippé S
J Neurooncol; 2024 May; 167(3):447-454. PubMed ID: 38443693
[TBL] [Abstract][Full Text] [Related]
6. Neuropsychological impact of trametinib in pediatric low-grade glioma: A case series.
Peterson RK; McKeown T; Tabori U; Bartels U; Bouffet E; Janzen L
Pediatr Blood Cancer; 2020 Dec; 67(12):e28690. PubMed ID: 32930446
[TBL] [Abstract][Full Text] [Related]
7. Trametinib for orbital plexiform neurofibromas in young children with neurofibromatosis type 1.
Toledano H; Dotan G; Friedland R; Cohen R; Yassur I; Toledano-Alhadef H; Constantini S; Rootman MS
Childs Nerv Syst; 2021 Jun; 37(6):1909-1915. PubMed ID: 33751171
[TBL] [Abstract][Full Text] [Related]
8. Response to trametinib treatment in progressive pediatric low-grade glioma patients.
Selt F; van Tilburg CM; Bison B; Sievers P; Harting I; Ecker J; Pajtler KW; Sahm F; Bahr A; Simon M; Jones DTW; Well L; Mautner VF; Capper D; Hernáiz Driever P; Gnekow A; Pfister SM; Witt O; Milde T
J Neurooncol; 2020 Sep; 149(3):499-510. PubMed ID: 33026636
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Trametinib-Associated Folliculitis Eruption With Fluconazole.
Steele C; Gershon T; Burkhart C; Googe P
JAMA Dermatol; 2020 Jun; 156(6):706-708. PubMed ID: 32267472
[No Abstract] [Full Text] [Related]
10. Trametinib for progressive pediatric low-grade gliomas.
Kondyli M; Larouche V; Saint-Martin C; Ellezam B; Pouliot L; Sinnett D; Legault G; Crevier L; Weil A; Farmer JP; Jabado N; Perreault S
J Neurooncol; 2018 Nov; 140(2):435-444. PubMed ID: 30097824
[TBL] [Abstract][Full Text] [Related]
11. Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma.
Knight T; Shatara M; Carvalho L; Altinok D; Poulik J; Wang ZJ
Pediatr Blood Cancer; 2019 Jan; 66(1):e27474. PubMed ID: 30251337
[No Abstract] [Full Text] [Related]
12. Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1.
Peacock BC; Tripathy S; Hanania HL; Wang HY; Sadighi Z; Patel AB
J Neurooncol; 2024 May; 167(3):515-522. PubMed ID: 38443692
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
Babovic-Vuksanovic D; Widemann BC; Dombi E; Gillespie A; Wolters PL; Toledo-Tamula MA; O'Neill BP; Fox E; MacDonald T; Beck H; Packer RJ
Pediatr Neurol; 2007 May; 36(5):293-300. PubMed ID: 17509460
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
16. Trametinib-associated Hyponatremia in a Child With Low-grade Glioma is Not Seen Following Treatment With Alternative MEK Inhibitor.
Lazow MA; Lawson SA; Salloum R; Hummel TR; Pillay Smiley N; DeWire-Schottmiller MD; Fouladi M; de Blank P
J Pediatr Hematol Oncol; 2021 May; 43(4):e550-e553. PubMed ID: 32520842
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Plexiform Neurofibromas with MEK Inhibitors: First Results with a New Therapeutic Option.
Vaassen P; Dürr NR; Rosenbaum T
Neuropediatrics; 2022 Feb; 53(1):52-60. PubMed ID: 34905788
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma.
Tolcher AW; Patnaik A; Papadopoulos KP; Rasco DW; Becerra CR; Allred AJ; Orford K; Aktan G; Ferron-Brady G; Ibrahim N; Gauvin J; Motwani M; Cornfeld M
Cancer Chemother Pharmacol; 2015 Jan; 75(1):183-9. PubMed ID: 25417902
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.
Infante JR; Fecher LA; Falchook GS; Nallapareddy S; Gordon MS; Becerra C; DeMarini DJ; Cox DS; Xu Y; Morris SR; Peddareddigari VG; Le NT; Hart L; Bendell JC; Eckhardt G; Kurzrock R; Flaherty K; Burris HA; Messersmith WA
Lancet Oncol; 2012 Aug; 13(8):773-81. PubMed ID: 22805291
[TBL] [Abstract][Full Text] [Related]
20. Trametinib Induces Neurofibroma Shrinkage and Enables Surgery.
Vaassen P; Dürr N; Röhrig A; Willing R; Rosenbaum T
Neuropediatrics; 2019 Oct; 50(5):300-303. PubMed ID: 31141829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
